Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19580441 | 0.83 | LOXL2 (0.50) | LOXL2ESR1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL30788376 | 0.82 | ESR1 (0.46) | ALDH1A1CYP3A4TSHRTDP1ESR1 | |
| SCHEMBL18428498 | 0.82 | ESR1 (0.46) | FDPSALDH1A1ESR1SLC6A2HTR2A | |
| SCHEMBL30972172 | 0.81 | FDPS (0.48) | FDPSALDH1A1CYP3A4GFERTSHR | |
| SCHEMBL295944 | 0.80 | ESR1 (0.44) | ALDH1A1TSHRTDP1ESR1MEN1 | |
| SCHEMBL563995 | 0.80 | ESR1 (0.44) | ALDH1A1ESR1ESR2TAAR1 | |
| SCHEMBL1068241 | 0.80 | ESR1 (0.70) | CYP3A4TSHRESR1SLC6A2SLC6A4 | |
| SCHEMBL21163625 | 0.79 | GFER (0.54) | FDPSALDH1A1CYP3A4GFERTSHR | |
| SCHEMBL247421 | 0.79 | IDO1 (0.45) | ALDH1A1CYP3A4ESR1SLC6A2HTR2A | |
| SCHEMBL22591635 | 0.79 | ALDH1A1 (0.52) | FDPSALDH1A1CYP3A4GFERTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11401286-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3842420-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2020-11-12 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| CN-1477960-A | EPA receptor inhibitors to treat rheumatoid arthritis | — | 2004-02-25 | — | — | CN | disclosed |
| CN-1476448-A | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ������ҩ������˾ | 2004-02-18 | — | — | CN | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | FDPS 208/4885ALDH1A1 1152/4885CYP3A4 248/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | FDPS 208/4885ALDH1A1 1152/4885CYP3A4 248/4885 |
| US-11401286-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | FDPS 208/4885ALDH1A1 1152/4885CYP3A4 248/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | FDPS 208/4885ALDH1A1 1152/4885CYP3A4 248/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | FDPS 2471/4885ALDH1A1 588/4885CYP3A4 320/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | FDPS 1790/4885ALDH1A1 1858/4885CYP3A4 376/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | FDPS 208/4885ALDH1A1 1152/4885CYP3A4 248/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | FDPS 208/4885ALDH1A1 1152/4885CYP3A4 248/4885 |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | FDPS 208/4885ALDH1A1 1152/4885CYP3A4 248/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | FDPS 1619/4885ALDH1A1 1286/4885CYP3A4 639/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | FDPS 4744/4885ALDH1A1 4184/4885CYP3A4 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.